Updated Priorities for Cerebroprotection Trials.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 41263084.
- Also identified by DOI 10.1161/STROKEAHA.125.052147.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A STAIR XIII (Stroke Treatment Academic Industry Roundtable) workshop was held to discuss aspects of trials likely to have the greatest impact on detecting meaningful treatment effects of cerebroprotection in acute stroke. Intended goals for hyperacute protection should be focused on preserving penumbral tissue and delaying infarct core growth to augment the impact of reperfusion therapies. Infarct volume is a biologically and clinically meaningful surrogate imaging marker to assess the treatment effects of cerebroprotection. Lastly, clinical outcome measures for cerebroprotection should include domain-specific and patient-centered outcomes to detect clinically meaningful changes across multiple functional domains.
Medical subject headings
- Stroke
- Clinical Trials as Topic
- Neuroprotective Agents